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Abstract
Background—Purkinje cell axonal swellings (“torpedoes”), described in several cerebellar
disorders as well as essential tremor (ET), have not been quantified in common neurodegenerative
conditions.
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Objective—To quantify torpedoes Parkinson’s disease (PD) and Alzheimer’s disease (AD)
compared with ET and control brains.
Methods—Brains included 40 ET cases (34 cerebellar ET, 6 Lewy body variant of ET) and age-
matched comparison brains (21 AD, 14 PD/diffuse Lewy body disease, 25 controls). Torpedoes were
counted in 20×25 mm cerebellar cortical sections stained with Luxol Fast Blue/Hematoxylin and
Eosin.
Results—The median number of torpedoes in cerebellar ET (12) was 12x higher than that of
controls (1) and nearly 2.5x higher than in AD (5) or PD/DLBD (5)(all p!0.005). Furthermore, in a
logistic regression model that adjusted for age and Alzheimer’s-type changes, each torpedo more
than doubled the odds of having cerebellar ET (Odds ratiocerebellar ET vs. control = 2.57, p = 0.006),
indicating that the association between increased torpedoes and cerebellar ET was independent of
these Alzheimer’s-type changes.
Conclusions—While torpedoes are increased in AD and PD, as well as cerebellar ET, the
magnitude of increase in cerebellar ET is greater, and cannot be accounted for by concomitant AD
or PD pathology.
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Introduction
Torpedoes, swellings of the proximal portion of the Purkinje cell axon, are presumed to
represent a cellular response to injury.1 These lesions have recently been described in patients
with essential tremor (ET), where their numbers have been shown to be several-fold higher
than seen in similarly-aged control brains.2, 3 Torpedoes have been described in several other
disorders including cerebellar damage from mercury toxicity, cerebellar ataxias, and
paraneoplastic cerebellar ataxia.4, 5 More broadly, the question arises as to whether these
lesions also occur in patients with common neurodegenerative conditions such as Alzheimer’s
disease (AD) and Parkinson’s disease (PD). This is particularly important because each of these
diseases, and especially AD, may co-occur in elderly patients with ET, confounding the
interpretation of results.6, 7 Cerebellar abnormalities have been reported in PD brains (alpha-
synuclein inclusions in Purkinje cell axons8 and Bergmann glial cells9). Various cerebellar
abnormalities have also been described in AD, including Purkinje cell loss and gliosis,10–12
and lipopigment changes.13 However, torpedoes have not been systematically assessed in
either of these diseases. Our aim was to quantify the number of torpedoes in postmortem
cerebellar tissue in patients with PD and AD, and to compare these to ET and control brains
of similar age. The underlying question is how specific these lesions are to ET, a disease whose
neuropathological underpinnings are only now beginning to emerge.3
Methods
Tissue was analyzed at the New York Brain Bank, Columbia University Medical Center. The
100 brains included ET (N = 40 [31 reported previously2]), AD (N = 21), PD or diffuse Lewy
body disease (DLBD) (N = 14) and controls (N = 25 [21 reported previously2]).
40 ET brains were obtained from the Essential Tremor Centralized Brain Repository (New
York Brain Bank).2, 14 As documented,2 brains were either collected prospectively beginning
in 2003 (N = 27) or banked elsewhere and then sent to the New York Brain Bank (N = 13
including the Royal University Hospital in Saskatchewan, Canada; the University of Kansas
Brain Bank; the Honolulu-Asia Aging Study; Southern Illinois University Brain Bank; the
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Veterans Administration West Los Angeles Healthcare Center; and Sunnybrook Health
Sciences Centre, Toronto, Canada). All but one had been diagnosed with ET by their treating
neurologist. All diagnoses were confirmed using Essential Tremor Centralized Brain
Repository criteria.2 One case fulfilled all clinical diagnostic criteria for ET,2 despite not having
received this diagnosis during life. Two additional ET cases that were included in an earlier
series2 and who fulfilled pathological criteria for PD, were not included in this series.
AD brains were from individuals who during life had been enrolled as AD cases in the
Alzheimer’s Disease Research Center or the Washington Heights Inwood Columbia Aging
Project, where they were followed prospectively with serial neurological assessments,
including assessment of action tremor, and were free of ET or PD. They were 1:2 age-matched
to ET brains, yielding 21 AD brains.
PD and DLBD brains at the New York Brain Bank had been patients at the Movement Disorder
Division, Neurological Institute of New York or were outside referrals to the brain bank. They
were 1:2 age-matched to ET brains, initially yielding 21 brains, but cerebellar tissue sections
were unavailable on 7, yielding 14 brains. The final 14 were similar to the excluded 7 in terms
of age and gender. These 14 had been diagnosed during life with PD (N = 4), PD with dementia
(N = 4), or diffuse Lewy body disease (N = 6).
Control brains were from individuals who had been enrolled as normal elderly control subjects
in the Alzheimer’s Disease Research Center or the Washington Heights Inwood Columbia
Aging Project, where they were followed prospectively with serial neurological assessments,
including assessment of action tremor, remaining free of a diagnosis of AD, ET or PD during
life, and not having a neuropathological diagnosis after autopsy. Twenty-five brains could be
age-matched to cerebellar ET cases.
Demographic and clinical information were collected on each case. All brains underwent
complete neuropathological assessment at the New York Brain Bank 2, 14–17 and were
processed according to methods optimizing the yield of fresh frozen samples for research.18
Brains received ratings of neurofibrillary tangles using Braak & Braak staging 19, 20 and
Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) ratings21 for neuritic
plaques; National Institute on Aging - Reagan Institute (NIA - RI) criteria for AD were
assigned.22 Braak PD stage was also assigned.23 Postmortem interval (PMI) was the number
of hours between death and placement of the brain in a cold room or upon ice. The Institutional
Review Board of Columbia University Medical Center approved study procedures.
As in previous studies,2, 16, 17, 24 a standard 3 × 20 × 25 mm parasagittal tissue block from
the neocerebellum (see Figure 5 in16 ) was harvested from each brain. Paraffin sections (7 µm
thick) were stained with Luxol Fast Blue counterstained with Hematoxylin and Eosin (LH&E)
for quantification of torpedoes.2, 16, 17 In each brain, torpedoes in one entire LH&E section
were counted, blinded to the clinical diagnosis. We have shown that counts on one section
correlate robustly with counts on other sections from the same cases (r = 0.86, p <0.001),
indicating that repeat sectioning and counting is likely to yield similar results.
As documented,2, 17, 24 ET cases were divided into two groups based on the presence vs.
absence of brainstem Lewy bodies on postmortem examination. We have demonstrated that
ET brains without Lewy bodies have an emerging array of cerebellar abnormalities that include,
but are not limited to, increased numbers of torpedoes. These abnormalities include a reduction
in the number of Purkinje cells25 (60% of normal),2, 24 swellings of Purkinje cell dendrites,2
heterotopic Purkinje cells,2 and in some cases, degenerative changes in the dentate nucleus.2,
16 Based on this picture, these Lewy body-free brains have been referred to as cerebellar ET
in previous publications,3 and we continue that nomenclature here.
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Data were analyzed in SPSS (Version 15.0). Number of torpedoes (LH&E) and PMI were not
normally distributed. Therefore, non-parametric tests (Spearman’s r, Mann-Whitney test) were
used for these variables. In logistic regression analyses, diagnosis (cerebellar ET case vs.
control) was the dependent variable, and number of torpedoes, the independent variable.
Results
The 100 brains included 40 ET (34 cerebellar ET and 6 LBVET), 21 AD, 14 PD or DLBD,
and 25 controls. Cerebellar ET cases and controls did not differ with regards to age; PD/DLBD
cases, AD cases and controls were also similar in age (Table 1). AD cases had lower brain
weights than controls (Table 1). CERAD plaque score was higher in AD cases than controls,
and Braak AD stage was higher in AD cases, cerebellar ET cases and LBVET cases than
controls (Table 1). All AD cases met NIA-RI pathological criteria for AD (CERAD plaque
score C and Braak stage V or higher); none of the ET cases, PD/DLBLD cases or controls met
these criteria. Among the 14 PD or DLBD cases, Braak PD stages were V (N = 3) and VI (N
= 11).
The median number of torpedoes in cerebellar ET cases was 12 times higher than that of
controls and was significantly higher than that of each of the other groups (Figure 1). It was
2.5 times higher than that of AD (p = 0.005) and 2.5 times that of PD/DLBD (p = 0.002). The
number of torpedoes in AD and PD/DLBD cases was intermediate between that seen in
cerebellar ET and controls, and was higher than that seen in controls (Table 1). The number in
Lewy body variant of ET did not differ from that of controls (Table 1). After combining all 40
ET brains into one group, the number of torpedoes was 10.5 times higher than seen in controls
(median = 10.5, mean = 13.3 ± 12.1, Mann Whitney z = 5.17, p < 0.001).
In these 100 brains, there was no association between number of torpedoes and age (r = 0.15,
p = 0.14), brain weight (r = "0.13, p = 0.19), PMI (r = 0.09, p = 0.46), Braak AD stage (r =
0.12, p = 0.25), CERAD plaque score (r = 0.16, p = 0.13), Braak PD stage (r = "0.13, p = 0.20)
or gender (Mann-Whitney = 1.48, p = 0.14). In cerebellar ET cases, number of torpedoes was
marginally associated with age of tremor onset (r = 0.28, p = 0.13) and marginally inversely
with tremor duration (r = "0.35, p = 0.06).
In a logistic regression model that was restricted to cerebellar ET cases and controls, each
torpedo nearly doubled the odds of cerebellar ET (odds ratio [OR] = 1.89, 95% confidence
interval [CI] = 1.31 – 2.73, p = 0.001). The odds remained elevated after adjusting for age,
Braak AD stage and CERAD score in a multivariate logistic regression model (OR = 2.57,
95% CI = 1.32 – 5.00, p = 0.006), indicating that the association between increased torpedoes
and cerebellar ET was independent of Alzheimer’s-type changes in the brain. To further
demonstrate this point, we stratified cerebellar ET cases and controls by CERAD plaque score
and Braak AD stage. Within each stratum of Alzheimer’s-type change, the number of torpedoes
in cerebellar ET was greater than that of controls (i.e., association between increased torpedoes
and ET was independent of Alzheimer’s-type changes in the brain). For example, CERAD
plaque score 0 (12.6 ± 13.4 torpedoes in cases vs. 1.9 ± 1.6 torpedoes in controls), CERAD
plaque score A (12.0 ± 5.5 vs. 2.0 ± 1.9), CERAD plaque score C (13.7 ± 4.7 vs. 4.0 ± 0.0),
and Braak AD stage 0 (15.0 ± 6.6 torpedoes in cases vs. 2.4 ± 1.9 torpedoes in controls), Braak
AD stage I (21.0 ± 18.5 vs. 1.4 ± 1.1), Braak AD stage III (10.3 ± 7.5 vs. 0.0 ± 0.0), and Braak
AD stage IV (8.4 ± 6.8 vs. 3.0 ± 0.0).
Discussion
This is the first systematic attempt to study these Purkinje cell lesions broadly, not only in ET,
but also in other common degenerative diseases. Torpedoes were more abundant in the AD
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and PD brain than control brains, indicating that these abnormalities may be found to some
extent in these neurodegenerative diseases. Yet this increased number was only a fraction of
that seen in cerebellar ET brains. Indeed, the number of torpedoes in cerebellar ET was 2 – 3
times higher than seen in AD and PD, indicating that the magnitude of increase in cerebellar
ET is not a feature of these other diseases. Furthermore, in analyses that accounted for Braak
AD stage and CERAD score, the association between increased torpedoes and cerebellar ET
was independent of Alzheimer’s-type changes in the brain, indicating that the cerebellar ET
vs. control difference is not due to the confounding effects of co-occurring Alzheimer’s-type
pathologies, which can occur in the ET brain.
Torpedoes are swellings of the proximal portion of the Purkinje cell axon. There is general
agreement that they occur in injured Purkinje cells; however, whether they represent a pre-
terminal cellular response or a regenerative response is not entirely clear.26, 27
Ultrastructurally, torpedoes are comprised of massive accumulations of neurofilaments, which
occur in disordered arrangements.26–28 In previous analyses, cerebellar ET brains
demonstrated an array of cerebellar abnormalities that included torpedoes;3 the diagnostic
utility of these abnormalities is currently under investigation.
Recent literature suggests that the odds of ET might be increased in individuals with PD.7,
29 Studies also suggest that ET and AD, as two common disorders, can co-occur, and some
recent data suggest that there are increased odds and increased risk of AD in individuals with
ET above and beyond that expected because of their high prevalences.6, 30 This has raised the
question as to whether the increased numbers of torpedoes that are seen in ET are due to
Alzheimer’s-type changes in ET brains; the current data suggest that this is not the case.
This study had limitations. First, the number of ET cases was small. However, this represents
the largest assembled collection of ET brains reported in the literature; the current series is
approximately double the size of previous series.25, 31 In addition, the sample size was adequate
for detecting statistically significant differences between cerebellar ET and each of the other
diagnostic groups, indicating that the sample size did not limit our ability to detect our main
effects. Second, while the cerebellar ET cases and controls did not differ significantly by age,
these cases were on average 5.2 years older than controls. However, we showed that number
of torpedoes was not correlated with age and, furthermore, the difference between cerebellar
ET cases and controls persisted in logistic regression models that adjusted for age. This study
also had unique features and strengths. It systematically studied these lesions broadly in ET as
well as other common degenerative diseases. Second, we carefully matched diseased cases
with similarly-aged control brains. Finally, in each diagnostic group, we documented AD-type
pathological changes in order to deal with this important confounding factor.
In summary, torpedoes occur in the AD and PD brain but not to the extent seen in cerebellar
ET. Nor do AD-type pathologies account for the abundance of torpedoes in the cerebellar ET
brain. Further studies of these lesions will be important to our understanding of the pathogenesis
of ET.
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Number of torpedoes per section by diagnosis. Using a standard 20 × 25 mm LH&E-stained
cerebellar section that included portions of the cerebellar cortex, white matter, and dentate
nucleus, torpedoes in the entire section were counted. The Y axis shows the mean number of
torpedoes per section ± one standard error.
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